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Abstract
Recent work shows that the inhibition of the SOS stress response in Escherichia coli reduces the
development of resistance to the antibiotics ciprofloxacin and rifampicin. This finding may help in
the battle against the rise of resistance to antimicrobial drugs.
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Bacterial resistance to antimicrobial drugs is currently
receiving much publicity and political attention. The cost to
health services around the world is counted in billions of
dollars; an increase in morbidity and mortality are the costs
to those infected. The problem is getting worse and treat-
ment options for combating bacteria resistant to multiple
drugs are narrowing. Unless something is done, we may well
return to the horrors of the pre-antibiotic era. In a recent
article, Cirz and colleagues [1] report the interesting finding
that the rate of resistance to some drugs in Escherichia coli
can be greatly reduced by interfering with a bacterial stress
response. This article sets the work by Cirz et al. [1] in the
general context of antimicrobial drug resistance and dis-
cusses whether this new finding could be helpful in the battle
against the rise of drug-resistant bacteria.
Are ‘mutation-busting’ drugs the answer to the
problem of drug resistance?
Resistance to antimicrobials occurs in four main ways (Figure
1). The first possible mechanism is the mutation of the drug’s
target; a classic example of this is the mutation of gyrA,
encoding the essential DNA gyrase A subunit, the major target
of quinolones such as ciprofloxacin in E. coli [2]. A second
mechanism is a bypass of the drug’s target by the acquisition of
a similar but insensitive target protein. A good example here
would be the acquisition of a plasmid-borne dihydrofolate
reductase (DHFR) insensitive to trimethoprim; the acquired
DHFR compensates for the inhibition of the host’s DHFR in
the presence of trimethoprim and is the predominant cause of
resistance to this antimicrobial drug in E. coli [3]. A third
mechanism is the enzymatic degradation or modification of the
drug; a well-known example is the destruction of -lactam
antibiotics by plasmid-mediated TEM -lactamase, which
accounts for around 90% of all ampicillin resistance in E. coli
[4]. And fourth, resistance can be caused by a nonspecific
reduced permeability to antimicrobial drugs. This is typically
caused by reduced production of porins, the protein channels
that allow antimicrobials through the outer bacterial
membrane, and/or an increased production of drug-efflux
pumps, which remove drugs from both cytoplasm and
periplasm [5]. These two events are often coordinated, for
example through the Mar regulon in E. coli, which - when
constitutively activated by mutation - leads to resistance to
multiple antimicrobial drugs [6].
Mutations are an unavoidable fact of life, but it has long
been known that gyrA mutations leading to ciprofloxacin
resistance in E. coli occur at a higher frequency than one
might expect given E. coli’s general rate of mutation [7]. One
process that leads to increased mutation in E. coli is the SOS
response, which is triggered in response to a wide range of
stress conditions. It is known to cause increased mutation
rates, particularly following DNA damage. The unblocking of
stalled replication forks, which are a common and poten-
tially lethal result of DNA damage, requires the SOS
response, for example. The trigger for the SOS response is
the autolytic degradation of the transcriptional repressor/
protease hybrid, LexA, thus derepressing the expression of a
group of genes whose products are responsible for DNA
repair and unblocking of stalled replication forks. These
proteins include error-prone DNA polymerases, whoseactivities lead to the increased frequency of mutation seen
in cells during the SOS response [8].
In their recent article, Cirz et al. [1] postulate that
ciprofloxacin induces DNA damage and so instigates the
SOS response, thereby increasing the frequency at which
ciprofloxacin-resistant mutants arise in E. coli. Through a
series of in vitro experiments, they confirmed that this is the
case, and that mutations in lexA that block the SOS response
result in a reduction in the apparent frequency of mutation
to ciprofloxacin resistance in vitro. Another lexA mutant
strain had the ciprofloxacin mutation frequency apparently
reduced to zero compared to the wild-type parent, when
tested in a murine model of infection [1].
The  gyrA mutations caused by ciprofloxacin-mediated
induction of the SOS response were all confirmed as being
base substitutions, typical of those seen in the clinic. Cirz et
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Figure 1
Antimicrobial drug-resistance mechanisms. A typical Gram-negative bacterial cell envelope is shown, consisting of the outer membrane, the peptidoglycan
cell wall, the periplasm, which contains enzymes required to synthesize the cell wall, and the cytoplasmic membrane. (a) The entry point and targets of
antimicrobial drugs in a non-resistant bacterium. Drugs enter the periplasm through porins in the outer membrane, and some drugs exert their effect in
the periplasm; for example, ampicillin and the other -lactams interfere with the synthesis of the cell wall. Other drugs cross the cytoplasmic membrane
and inhibit cytoplasmic targets. (b) Possible resistance mechanisms: (1) Mutation of a target so that it is no longer inhibited by the drug; (2) acquisition,
for example on a plasmid, of a novel target that is not sensitive to the actions of the drug; (3) enzymatic destruction or modification of the drug either in
the cytoplasm, for example, the inactivation of gentamicin by aminoglycoside-modifying enzymes, or in the periplasm, for example, the destruction of -
lactams by -lactamase;  (4) reduction of the cytoplasmic, and usually periplasmic, concentration of the drug through reduction in the expression of porin
genes or loss-of-function mutations in porin genes; (5) removal of drugs from the periplasm or cytoplasm by efflux pumps. In some cases, drug resistance
is due to a combination of these mechanisms. 
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Efflux pumpal. [1] postulate, however, that ciprofloxacin also induces
some other repair system, which causes small deletions, as
some of the ciprofloxacin-resistant mutants had deletions
of entire triplets in gyrA. Such mutants are not seen clini-
cally, and it is highly likely that they come with an extreme
fitness cost. 
The authors found the same pattern of results when looking
at the frequency of occurrence of rifampicin-resistant
mutants caused by point mutations in the rpoB gene
encoding the beta subunit of RNA polymerase. This is
perhaps surprising, because rifampicin does not cause DNA
damage, being an inhibitor of RNA polymerase. Several
antibiotics are, however, known to cause metabolic stress
and induce the SOS response without overtly causing DNA
damage; these include for example, the -lactams [9].
The work of Cirz et al. [1] at least opens up the possibility
that inhibitors of the SOS response might represent drugs
that reduce point mutation rates in bacteria, and so reduce
the frequency with which drug-resistant mutations occur.
But would this really be of benefit? Taking the example of
quinolone resistance in E. coli, the answer is ‘yes and no’. As
well as target-site mutations, efflux pump and/or porin
regulatory mutations can cause antimicrobial drug resistance
[5], so mutation-busting drugs could be doubly helpful. On
the other hand, mutations are not the only cause of resistance.
For example, mobile genetic elements can cause quinolone
resistance in two main ways. First, the insertion of mobile IS
elements can derepress efflux-pump gene expression and
disrupt porin genes [5]. Second, plasmid-mediated
quinolone-resistance determinants are becoming increasingly
common; these encode proteins that bind to the active sites
of quinolone targets and occlude the drugs [10]. Indeed,
there are no classes of antimicrobial drug for which point
mutations are the sole reason for the development of
resistance. So the best one can say is that mutation-busting
drugs would reduce the development of resistance due to
mutation. They would, however, do nothing to prevent the
development of resistance due to mobile genetic elements.
Furthermore, it is likely that by the time they have been
developed, many of the mutations they are designed to stop
will already have occurred.
Other approaches to solving the problem of
antimicrobial drug resistance
Other strategies for combating antimicrobial drug resistance
fall into three main types. First, simply develop new drugs.
The post-genomic era has led to the discovery of a whole host
of essential genes in bacteria whose products might represent
targets for novel antimicrobial drugs. But the exploitation of
these targets is proving very difficult. More useful has been
the adaptation of known drug scaffolds so that they overcome
existing resistance mechanisms [11,12]. It is, however,
unlikely that permeability-mediated resistance mechanisms
of Gram-negative bacteria will be overcome by these new
drug variants, as these resistance mechanisms affect a
broad spectrum of antibiotics [5]. The second approach is to
stop using a particular drug and reintroduce it when resistance
levels have fallen. This idea derives from the assumption
that resistance mechanisms come with a fitness cost and
that in the absence of selection, resistant strains will be
out-competed by sensitive strains. Recent work has
revealed, however, that most resistance mechanisms
impose no significant fitness cost; indeed some may provide
a fitness advantage [13,14], and this may explain why sulfon-
amide-resistance levels in E. coli did not fall in the UK even
10 years after the use of sulfonamides had been discontinued
[15]. The third strategy is to learn more about the resistance
mechanisms themselves. This area of research is focused on
degradative enzymes and efflux pumps. The -lactamase
inhibitors already used clinically have been most successful
but do not inhibit a large swathe of these enzymes, so more
are required [16]; efflux-pump inhibitors exist but are not
currently in a clinically useful form [17]. 
In conclusion, the problem of antimicrobial drug resistance
is very real, and is set to get worse before it gets better. The
more we learn about the responses of bacteria to antimicro-
bial challenge, and about the fundamental mechanisms of
drug resistance in bacteria, the more likely we are to be able
to develop strategies for reducing the burden of resistance.
The availability of large amounts of complete bacterial
genome sequence data, coupled with the development of
post-genomic technologies aimed at comparing gene com-
plements and gene-expression patterns in resistant and
non-resistant bacteria (for example [18,19]), gives us an
excellent platform to study resistance mechanisms. So, the
dawn of the post-genomic era may help to delay a return to
the pre-antibiotic era. Only time will tell.
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